1.Response Evaluation of Chemotherapy for Lung Cancer.
Tuberculosis and Respiratory Diseases 2017;80(2):136-142
Assessing response to therapy allows for prospective end point evaluation in clinical trials and serves as a guide to clinicians for making decisions. Recent prospective and randomized trials suggest the development of imaging techniques and introduction of new anti-cancer drugs. However, the revision of methods, or proposal of new methods to evaluate chemotherapeutic response, is not enough. This paper discusses the characteristics of the Response Evaluation Criteria In Solid Tumor (RECIST) version 1.1 suggested in 2009 and used widely by experts. It also contains information about possible dilemmas arising from the application of response assessment by the latest version of the response evaluation method, or recently introduced chemotherapeutic agents. Further data reveals the problems and limitations caused by applying the existing RECIST criteria to anti-cancer immune therapy, and the application of a new technique, immune related response criteria, for the response assessment of immune therapy. Lastly, the paper includes a newly developing response evaluation method and suggests its developmental direction.
Drug Therapy*
;
Evaluation Studies as Topic
;
Lung Neoplasms*
;
Lung*
;
Methods
;
Prospective Studies
;
Response Evaluation Criteria in Solid Tumors
2.Optimal Phase of Dynamic Computed Tomography for Reliable Size Measurement of Metastatic Neuroendocrine Tumors of the Liver: Comparison between Pre- and Post-Contrast Phases.
Jimi HUH ; Jisuk PARK ; Kyung Won KIM ; Hyoung Jung KIM ; Jong Seok LEE ; Jong Hwa LEE ; Yoong Ki JEONG ; Atul B SHINAGARE ; Nikhil H RAMAIYA
Korean Journal of Radiology 2018;19(6):1066-1076
OBJECTIVE: The reliability of size measurements of liver metastases from neuroendocrine tumors (NETs) on contrast-enhanced computed tomography (CT) phases made by different readers may be hampered due to transient, variable rim enhancement in arterial phase (AP) or portal venous phase (PVP) images. We aimed to assess the reliability of tumor size measurements in pre- and post-contrast scans. MATERIALS AND METHODS: The study coordinator selected target lesions according to Response Evaluation Criteria in Solid Tumors 1.1 guidelines in 44 consecutive patients with pathologically confirmed NET liver metastases. Two blinded readers measured the longest diameters of target lesions on pre-contrast, AP, and PVP images twice with a 4-week interval. Inter- and intra-observer agreements were evaluated using Bland-Altman plots and 95% limit of agreement (LOA) calculations. RESULTS: Of the 79 target lesions (approximate mean size of 3 cm), 45 showed rim enhancement. Inter-observer agreement assessed based on LOA was highest in pre-contrast CT images (−6.1–5.7 mm), followed by PVP (−7.9–7.1 mm) and AP (−8.5–7.4 mm) images. Intra-observer agreement showed the same trend: −2.8–2.9 mm and −2.9–2.9 mm for readers 1 and 2, respectively, on pre-contrast CT, −2.8–2.9 mm and −3.0–3.2 mm, respectively, on PVP, and −3.2–4.2 mm and −3.4–3.2 mm, respectively, on AP images. Mean tumor diameters differed significantly among the phases in the following increasing order: pre-contrast CT, PVP, and AP images. CONCLUSION: There was better inter- and intra-observer agreement in size measurements of NET liver metastases on precontrast scans than on AP and PVP scans. Pre-contrast CT may be the optimal for measuring NET liver metastases if its accuracy is proven.
Humans
;
Liver*
;
Loa
;
Neoplasm Metastasis
;
Neuroendocrine Tumors*
;
Response Evaluation Criteria in Solid Tumors
3.The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE.
Jung Hee KIM ; Dong Hyun SINN ; Sung Wook SHIN ; Sung Ki CHO ; Wonseok KANG ; Geum Youn GWAK ; Yong Han PAIK ; Joon Hyeok LEE ; Kwang Cheol KOH ; Seung Woon PAIK ; Moon Seok CHOI
Clinical and Molecular Hepatology 2017;23(1):42-50
BACKGROUND/AIMS: We investigated the outcomes of early-stage hepatocellular carcinoma (HCC) patients who showed a complete response (CR) to initial transarterial chemoembolization (TACE), with a focus on the role of scheduled TACE repetition. METHODS: A total of 178 patients with early-stage HCC who were initially treated with TACE and showed a CR based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria on one month follow-up computed tomography (CT) were analyzed. Among them, 90 patients underwent scheduled repetition of TACE in the absence of viable tumor on CT. RESULTS: During a median follow-up period of 4.6 years (range: 0.4-8.8 years), mortality was observed in 71 patients (39.9%). The overall recurrence-free and local recurrence-free survival rates at 1 year were 44.4% and 56.2%. In the multivariable model, scheduled repetition of TACE was an independent factor associated with survival (hazard ratio [95% confidence interval]: 0.56 [0.34-0.93], P=0.025). When stratified using Barcelona clinic liver cancer (BCLC) stage, scheduled repetition of TACE was associated with a favorable survival rate in BCLC stage A patients, but not in BCLC 0 patients. CONCLUSIONS: Scheduled repetition of TACE was associated with better survival for early-stage HCC patients showing a CR after initial TACE, especially in BCLC stage A patients.
Carcinoma, Hepatocellular*
;
Follow-Up Studies
;
Humans
;
Liver Neoplasms
;
Mortality
;
Response Evaluation Criteria in Solid Tumors
;
Survival Rate
4.Role of Nonsteroidal Anti-inflammatory Drug in Treatment of Extra-abdominal Desmoid Tumors.
Ja Young CHO ; Sanjay GUPTA ; Hwan Seong CHO ; Min Suk PARK ; Su Jung MOK ; Ilkyu HAN ; Han Soo KIM
Clinics in Orthopedic Surgery 2018;10(2):225-233
BACKGROUND: We retrospectively reviewed the outcomes of patients who had been treated with meloxicam for the extra-abdominal desmoid tumors and evaluated the correlation between clinical outcome and clinic pathological variables. METHODS: Twenty patients treated with meloxicam were followed up every 3 to 6 months. Meloxicam administration was planned at 15 mg/day orally for 6 months. RESULTS: Of the 20 patients evaluated, according to Response Evaluation Criteria in Solid Tumors criteria, there were five patients with partial response (25.0%), eight with stable disease (40.0%), and seven with tumor progression (35.0%). The cumulative probability of dropping out from our nonsurgical strategy using meloxicam was 35.0% at 1 year and 35.0% at 5 years. CONCLUSIONS: The present study suggests that conservative treatment would be a primary treatment option for this perplexing disease even though we were not able to determine that the use of a cyclooxygenase-2 inhibitor would have an additional influence on the natural course of a desmoid tumor.
Cyclooxygenase 2
;
Fibromatosis, Aggressive*
;
Humans
;
Response Evaluation Criteria in Solid Tumors
;
Retrospective Studies
5.Initial clinical outcomes of proton beam radiotherapy for hepatocellular carcinoma
Jeong Il YU ; Gyu Sang YOO ; Sungkoo CHO ; Sang Hoon JUNG ; Youngyih HAN ; Seyjoon PARK ; Boram LEE ; Wonseok KANG ; Dong Hyun SINN ; Yong Han PAIK ; Geum Youn GWAK ; Moon Seok CHOI ; Joon Hyeok LEE ; Kwang Cheol KOH ; Seung Woon PAIK ; Hee Chul PARK
Radiation Oncology Journal 2018;36(1):25-34
PURPOSE: This study aimed to evaluate the initial outcomes of proton beam therapy (PBT) for hepatocellular carcinoma (HCC) in terms of tumor response and safety. MATERIALS AND METHODS: HCC patients who were not indicated for standard curative local modalities and who were treated with PBT at Samsung Medical Center from January 2016 to February 2017 were enrolled. Toxicity was scored using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Tumor response was evaluated using modified Response Evaluation Criteria in Solid Tumors (mRECIST). RESULTS: A total of 101 HCC patients treated with PBT were included. Patients were treated with an equivalent dose of 62–92 GyE10. Liver function status was not significantly affected after PBT. Greater than 80% of patients had Child-Pugh class A and albumin-bilirubin (ALBI) grade 1 up to 3-months after PBT. Of 78 patients followed for three months after PBT, infield complete and partial responses were achieved in 54 (69.2%) and 14 (17.9%) patients, respectively. CONCLUSION: PBT treatment of HCC patients showed a favorable infield complete response rate of 69.2% with acceptable acute toxicity. An additional follow-up study of these patients will be conducted.
Carcinoma, Hepatocellular
;
Follow-Up Studies
;
Humans
;
Liver
;
Proton Therapy
;
Protons
;
Radiotherapy
;
Response Evaluation Criteria in Solid Tumors
6.Expanding Indications of Endoscopic Submucosal Dissection for Early Gastric Cancer: Hope or Hype?.
Gut and Liver 2015;9(2):135-136
No abstract available.
Dissection/*methods
;
Female
;
Gastric Mucosa/*surgery
;
Gastroscopy/*methods
;
Humans
;
Male
;
*Response Evaluation Criteria in Solid Tumors
;
Stomach Neoplasms/*surgery
7.Expanding Indications of Endoscopic Submucosal Dissection for Early Gastric Cancer: Hope or Hype?.
Gut and Liver 2015;9(2):135-136
No abstract available.
Dissection/*methods
;
Female
;
Gastric Mucosa/*surgery
;
Gastroscopy/*methods
;
Humans
;
Male
;
*Response Evaluation Criteria in Solid Tumors
;
Stomach Neoplasms/*surgery
8.A Case of Advanced Hepatocellular Carcinoma with Portal Vein Tumor Invasion that Showed Favorable Prognosis after Combined External Radiation Therapy and Sorafenib Therapy.
Namyoung PAIK ; Dong Hyun SINN ; Hee Chul PARK ; Woo Kyung JEONG ; Min Sun KIM ; Ji Hye KIM ; Bumhee YANG
Journal of Liver Cancer 2016;16(2):134-138
A prognosis of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is dismal that the median survival is 2 to 4 months without treatment. Sorafenib, the standard regimen of advanced HCC, can prolong median survival only 1.5 months. A 50-year-old man with a history of chronic hepatitis B was diagnosed advanced HCC with PVTT. By a multidisciplinary medical team approach, the combination of 3-demensional conformal radiation therapy with sequential sorafenib was challenged. 4 months after initiation of treatment, he achieved partial response as modified response evaluation criteria in solid tumors criteria. Sorafenib was continued so far, and stable disease has been maintained up to now, without significant adverse effect.
Carcinoma, Hepatocellular*
;
Hepatitis B, Chronic
;
Humans
;
Middle Aged
;
Portal Vein*
;
Prognosis*
;
Response Evaluation Criteria in Solid Tumors
;
Thrombosis
9.Evaluation of RECIST, PERCIST, EORTC, and MDA Criteria for Assessing Treatment Response with Ga68-PSMA PET-CT in Metastatic Prostate Cancer Patient with Biochemical Progression: a Comparative Study
Manoj GUPTA ; Partha Sarathi CHOUDHURY ; Sudhir RAWAL ; Harish Chandra GOEL ; S Avinash RAO
Korean Journal of Nuclear Medicine 2018;52(6):420-429
PURPOSE: The aim of the study was to compare response evaluation criteria in solid tumours 1.1 (RECIST 1.1), positron emission tomography response criteria in solid tumours (PERCIST), European organisation for research and treatment of cancer (EORTC), andMDAnderson (MDA) criteria for response assessment by Gallium 68-prostate-specific membrane antigen positron emission tomography-computed tomography (Ga68-PSMA PET-CT) in metastatic adenocarcinoma prostate cancer (mPCa) patients with biochemical progression.METHODS: Eighty-eight mPCa patients with pre and post treatment Ga68-PSMA PET-CTwere included. A ≥ 25% increase and ≥ 2 ng/ml above the nadir if prostate specific antigen (PSA) drop or ≥ 2 ng/ml above the baseline if PSA does not drop was considered as biochemical progression. RECIST 1.1 and MDA criteria for morphology and PERCIST and EORTC criteria for molecular response were investigated. Percentages of progressive disease (PD), partial response (PR), and stable disease (SD) were calculated. Chi-square test was used for statistical significance.RESULTS: Proportion of PD, SD, and PR by RECIST 1.1 and MDA criteria were 44 (50.57%), 39 (44.83%), 4 (4.6%), and 33 (39.76%), 48 (57.83%), 2 (2.41%) respectively. Proportion of PD, SD, and PR by PERCIST and EORTC criteria were 71 (80.68%), 11 (12.50%), 6 (6.82%), and 74 (84.09%), 8 (9.09%), 6 (6.82%) respectively. Chi-square test showed statistically significant (P < 0.05) higher proportion of progression detected by both molecular criteria as compare to both morphological criteria.CONCLUSION: We concluded that for Ga68-PSMA PET-CT response evaluation, molecular criteria performed better than morphological criteria in mPCa patient with PSA progression.
Adenocarcinoma
;
Electrons
;
Gallium
;
Humans
;
Membranes
;
Positron-Emission Tomography
;
Prostate
;
Prostate-Specific Antigen
;
Prostatic Neoplasms
;
Response Evaluation Criteria in Solid Tumors
10.Evaluation of response to stereotactic radiosurgery in patients with radioresistant brain metastases
Mutlay SAYAN ; Teuta ZOTO MUSTAFAYEV ; Bilgehan SAHIN ; Erva Seyma Sare KEFELIOGLU ; Shang Jui WANG ; Varsha KURUP ; Aykut BALMUK ; Gorkem GUNGOR ; Nisha OHRI ; Joseph WEINER ; Enis OZYAR ; Banu ATALAR
Radiation Oncology Journal 2019;37(4):265-270
PURPOSE: Renal cell carcinoma (RCC) and melanoma have been considered ‘radioresistant’ due to the fact that they do not respond to conventionally fractionated radiation therapy. Stereotactic radiosurgery (SRS) provides high-dose radiation to a defined target volume and a limited number of studies have suggested the potential effectiveness of SRS in radioresistant histologies. We sought to determine the effectiveness of SRS for the treatment of patients with radioresistant brain metastases.MATERIALS AND METHODS: We performed a retrospective review of our institutional database to identify patients with RCC or melanoma brain metastases treated with SRS. Treatment response were determined in accordance with the Response Evaluation Criteria in Solid Tumors.RESULTS: We identified 53 radioresistant brain metastases (28% RCC and 72% melanoma) treated in 18 patients. The mean target volume and coverage was 6.2 ± 9.5 mL and 95.5% ± 2.9%, respectively. The mean prescription dose was 20 ± 4.9 Gy. Forty lesions (75%) demonstrated a complete/partial response and 13 lesions (24%) with progressive/stable disease. Smaller target volume (p < 0.001), larger SRS dose (p < 0.001), and coverage (p = 0.008) were found to be positive predictors of complete response to SRS.CONCLUSION: SRS is an effective management option with up to 75% response rate for radioresistant brain metastases. Tumor volume and radiation dose are predictors of response and can be used to guide the decision-making for patients with radioresistant brain metastases.
Brain
;
Carcinoma, Renal Cell
;
Humans
;
Melanoma
;
Neoplasm Metastasis
;
Prescriptions
;
Radiosurgery
;
Response Evaluation Criteria in Solid Tumors
;
Retrospective Studies
;
Tumor Burden